Table 1.
The primers and primary antibody used in this study
|
Gene symbles |
Primers for RT-PCR |
|
Antibodies for IHC |
|
|
|
|---|---|---|---|---|---|---|
| Primer sequences | Annealing temperature (°C) | Antibody sources | Clone | Dilution | ||
| Bmi1 |
Reverse |
5’-ATT GTC TTT TCC GCC CGC TT-3’ |
58.2 |
ProMab Biotechnologies Inc |
3E3 |
1:800 |
| Forward |
5’-TGG CAT CAA TGA AGT ACC CTC-3’ |
|||||
| CD44 |
Reverse |
5’-TGC TAC TGA TTG TTT CAT TGC G-3’ |
56.2 |
ProMab Biotechnologies Inc |
8E2F3 |
1:30000 |
| Forward |
5’-GGA CCA GGC CCT ATT AAC CC-3’ |
|||||
| CD133 |
Reverse |
5’-AAA CAA TTC ACC AGC AAC GAG-3’ |
54.1 |
ProMab Biotechnologies Inc |
3 F10 |
1:400 |
| Forward |
5’-TAG TAC TTA GCC AGT TTT ACC G-3’ |
|||||
| Sox2 |
Reverse |
5’- GCT AGT CTC CAA GCG ACG AA-3’ |
56.2 |
ProMab Biotechnologies Inc |
10 F10 |
1:800 |
| Forward |
5’- TAC AGT CTA AAA CTT TTG CCC TT-3’ |
|||||
| Nanog |
Reverse |
5’-AGG CAA CTC ACT TTA TCC CAA-3’ |
54.1 |
Cell signaling technology |
D73G4 |
1:300 |
| Forward |
5’-GAT TCT TTA CAG TCG GAT GCT T-3’ |
|||||
| Oct-4 |
Reverse |
5’-TGC AGA AAG AAC TCG AGC AA-3’ |
56.2 |
Santa Cruz Biotechnology |
C-10 |
1:50 |
| Forward |
5’-CTC ACT CGG TTC TCG ATA CTG G-3’ |
|||||
| Msi2 |
Reverse |
5’-CAG ACC TCA CCA GAT AGC CTT-3’ |
56.2 |
ProMab Biotechnologies Inc |
2C11 |
1:1000 |
| Forward |
5’-TAC TGT GTT CGC AGA TAA CCC-3’ |
|||||
| β-actin (217 bp) |
Reverse |
5’GTG ACG TGG ACA TCC GCA AAG-3’ |
60.2 |
|
|
|
| Forward |
5’-ATC CAC ATC TGC TGG AAG GTG GAC-3’ |
|
|
|
||
| β-actin (417 bp) |
Reverse |
5’-ACA GAG CCT CGC CTT TGC CGA TC-3’ |
60.2 |
|
|
|
| Forward | 5’-TGG GTC ATC TTC TCG CGG TTG G-3’ | |||||